Cargando…
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8(+) and CD4(+) T cells
The success of immune system‐based cancer therapies depends on a broad immune response engaging a range of effector cells and mechanisms. Immune mobilizing monoclonal T cell receptors (TCRs) against cancer (ImmTAC™ molecules: fusion proteins consisting of a soluble, affinity enhanced TCR and an anti...
Autores principales: | Boudousquie, Caroline, Bossi, Giovanna, Hurst, Jacob M., Rygiel, Karolina A., Jakobsen, Bent K., Hassan, Namir J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629433/ https://www.ncbi.nlm.nih.gov/pubmed/28640942 http://dx.doi.org/10.1111/imm.12779 |
Ejemplares similares
-
ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing
por: Donnellan, Zoe, et al.
Publicado: (2015) -
ImmTACs: Novel bi-specific agents for targeted cancer therapy
por: Oates, Joanne, et al.
Publicado: (2013) -
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules
por: Harper, Jane, et al.
Publicado: (2018) -
Polyfunctional CD4(+) T Cells As Targets for Tuberculosis Vaccination
por: Lewinsohn, Deborah A., et al.
Publicado: (2017) -
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
por: McCormack, Emmet, et al.
Publicado: (2012)